Human Chorionic Gonadotropin (hCG) — CPB 1081 | AETNA Coverage Update

Aetna modified CPB 1081 governing human chorionic gonadotropin (hCG) coverage, effective December 4, 2025. Here's what billing teams need to know before claims go out the door.

Aetna, a CVS Health company, updated its hCG coverage policy under CPB 1081 to clarify medical necessity criteria across four approved indications — ART/ovulation induction, prepubertal cryptorchidism, hypogonadotropic hypogonadism, and steroid-refractory acute graft-versus-host disease. The primary billing code for hCG injections is HCPCS J0725, though claims also touch CPT codes 84702, 84703, 0167U, 58974, and 89255 depending on context. If your practice bills for fertility treatments, reproductive endocrinology, or oncology-adjacent care, this policy change deserves your attention before December 4, 2025.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna
Policy	Human Chorionic Gonadotropin (hCG) — CPB 1081
Policy Code	CPB 1081
Change Type	Modified
Effective Date	December 4, 2025
Impact Level	High
Specialties Affected	Reproductive endocrinology, fertility, urology, pediatric urology, hematology/oncology
Key Action	Verify precertification is in place for J0725 before December 4, 2025 and confirm your diagnosis codes match the four approved indications

---

Aetna hCG Coverage Criteria and Medical Necessity Requirements 2025

The Aetna hCG coverage policy under CPB 1081 covers four indications — and only four. Everything else is experimental. That's the line your billing team needs to hold.

Indication 1: ART and Ovulation Induction

Aetna covers hCG for induction of oocyte maturation and/or release when the member is undergoing assisted reproductive technology or ovulation induction. This is the highest-volume indication for most practices billing J0725. Watch the plan-level benefit exclusion on infertility injectable medications — many Aetna plans cover infertility procedures but carve out injectable drugs. Confirm the member's specific plan covers injectables before you bill.

Indication 2: Prepubertal Cryptorchidism

Aetna covers hCG for prepubertal cryptorchidism treatment. This indication is straightforward and has no stacked criteria. If the member is prepubertal and the diagnosis supports undescended testes, you meet the bar.

Indication 3: Hypogonadotropic Hypogonadism

This one has a two-part test. Medical necessity requires that the member has both low pretreatment testosterone levels AND low or low-to-normal FSH or LH levels. Both conditions must be documented. If you're billing for hypogonadotropic hypogonadism and only have testosterone labs in the chart, Aetna will deny the claim. Get FSH or LH values documented before precertification.

Indication 4: Steroid-Refractory Acute Graft-Versus-Host Disease

This is the newer and narrower indication. Aetna covers hCG for steroid-refractory acute graft-versus-host disease (ICD-10 D89.810) when either: the member takes hCG alongside systemic corticosteroids, OR the member has an intolerance or contraindication to systemic corticosteroids. This is an either/or test. Document which pathway applies in the prior authorization request.

Precertification Is Mandatory

Prior authorization applies to Novarel, Pregnyl, Ovidrel, and generic chorionic gonadotropin for all Aetna participating providers in applicable plans. Call (866) 782-2779 or fax (860) 754-2515 to initiate. Missing this step guarantees a claim denial.

The ART Bypass Rule — and Its Limits

Aetna has a benefit alignment rule for ART drugs. If the infertility procedure itself has been approved under the member's medical benefit, you can bypass specialty pharmacy medical necessity review for the accompanying drug. You'll need the medical authorization number from the procedure approval to do this. But some Aetna plans opt out of this bypass entirely. Those members go through full specialty pharmacy medical necessity review regardless. Check plan-level rules before assuming the bypass applies.

---

Aetna hCG Exclusions and Non-Covered Indications

Aetna considers all hCG indications not listed above to be experimental, investigational, or unproven. Full stop.

Two specific exclusions are embedded in the code table and matter for billing. hCG therapy is not covered when used solely for endometrium preparation for embryo transfer (CPT 58974 and 89255). If hCG is prescribed only to prepare the endometrium — and there's no covered ART indication driving it — you're outside the policy. Document the primary clinical purpose carefully.

The ICD-10 code list includes a large block of obesity and BMI codes (E66.x and Z68.x). The presence of these codes in the policy data signals that hCG for weight loss is explicitly on Aetna's radar — and not covered. hCG injections marketed for weight management have circulated in cash-pay practices for years. Billing Aetna for J0725 against obesity diagnoses will not result in reimbursement under CPB 1081.

---

Coverage Indications at a Glance

---

Aetna hCG Billing Guidelines and Action Items 2025

These are the steps your billing and authorization teams need to take before December 4, 2025.

Copy Action Items

If you're managing a mixed-payer practice with significant Aetna volume in reproductive endocrinology or oncology, loop in your compliance officer before the effective date. The GVHD indication in particular may be new territory for some billing teams, and the documentation requirements are specific.

---

CPT, HCPCS, and ICD-10 Codes for hCG Under CPB 1081

Covered HCPCS Code (When Selection Criteria Are Met)

Code	Type	Description Copy
J0725	HCPCS	Injection, chorionic gonadotropin, per 1,000 USP units

Other CPT Codes Related to CPB 1081

These codes appear in the policy but carry specific restrictions. CPT 58974 and 89255 include explicit notes that hCG therapy is not covered when used solely for endometrium preparation for embryo transfer.

Key ICD-10-CM Diagnosis Codes

---